MDTF is a non-cleavable antibody-drug conjugates (ADCs)[1].
MDTF (50 μM) increases drophilic character by substitution of a cyclohexyl ring and a MD-based FRET probe incubates in human plasma has a considerably higher self-stabilization rate compared to the MCC-based probe[1].
[1]. Dovgan I, et, al. 2-(Maleimidometl)-1,3-Dioxanes (MD): a Serum-Stable Self-drolysable drophilic Alternative to Classical Maleimide Conjugation. Sci Rep. 2016 Aug 9;6:30835.